Home › Cancro metastatico › Washington
Studi clinici su Cancro metastatico nello stato di Washington
47 studi su Cancro metastatico cercano partecipanti presso sedi nello stato di Washington.
Città nello stato di Washington
- Seattle39 studi
- Tacoma9 studi
- Kirkland6 studi
- Vancouver4 studi
- Spokane Valley4 studi
- Renton3 studi
- Spokane3 studi
Testo ufficiale dello studio (inglese)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
- Swedish Cancer Institute-Edmonds, Edmonds
- Swedish Cancer Institute-Issaquah, Issaquah
- Providence Regional Cancer System-Lacey, Lacey
- e altri 4
In reclutamentoFase 2
Tutte le età · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT05564377The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- University of Washington, Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT04585750Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- University of Washington Fred Hutchinson Cancer Center, Seattle
- Northwest Cancer Specialists, Vancouver
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07562152A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
- Research Site, Puyallup
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07205822A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
- Swedish Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT06234605Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT06625775Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06943755Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
- Northwest Medical Specialties, PLLC, Bonney Lake
- Swedish Cancer Institute - Edmonds Campus, Edmonds
- Swedish Medical Center - Edmonds, Edmonds
- e altri 9
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07222800A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- Swedish Cancer Institute, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07277413Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Northwest Cancer Specialists, P.C., Vancouver
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07222566A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
- Virginia Mason Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center, Seattle
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06989437A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
- Research Site, Tacoma
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06103864ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT07007559A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)
- University of Washington / Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 24 set 2026 · NCT05118789A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
- Swedish Cancer Institute - Edmonds, Edmonds
- Providence Regional Cancer Partnership, Everett
- UW Medicine Valley Medical Center, Renton
- e altri 5
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07174336SLV-154 Treatment of Advanced Cancers
- University of Washington / Fred Hutchinson Cancer Center, Seattle
- Northwest Medical Specialties, PLLC, Tacoma
In reclutamentoFase 1
Età 12 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT06771219A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Swedish Medical Center, Seattle
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07213804Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- Fred Hutchinson Cancer Center, Seattle
- University Of Washington Medical Center, Seattle
- Northwest Cancer Specialists, P.C., Vancouver
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT07227415A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
- Fred Hutchinson Cancer Center ( Site 0013), Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 set 2026 · NCT06863272A Study of KK2269 in Adult Participants With Solid Tumors
- University of Washington, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 10 set 2026 · NCT06266299A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Swedish Cancer Institute - Edmonds, Edmonds
- Kadlec Clinic Hematology and Oncology, Kennewick
- Swedish Medical Center, Seattle
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06119581AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)
- Avenzo Therapeutics Recruiting Site, Seattle
In reclutamentoFase 1/2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 4 set 2026 · NCT07038343Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- Cancer Care Northwest-1 (601 S. Sherman), Spokane
- Cancer Care Northwest_2 (605 E. Holland), Spokane
- Cancer Care Northwest, Spokane Valley
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 set 2026 · NCT06072612A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 24 ago 2026 · NCT06803680Mobile Health Application (PACT) to Improve Engagement in Advance Care Planning
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoVolontari sani benvenuti
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 ago 2026 · NCT04515810Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
- Fred Hutchinson Cancer Center, Seattle
- University of Washington Medical Center - Montlake, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 ago 2026 · NCT05687110Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
- Research Site, Kennewick
- Research Site, Seattle
In reclutamentoFase 3
Età 18 e oltre · Donne · Aggiornato il 29 lug 2026 · NCT07044336A Study of ASP1002 in Adults for Treatment of Solid Tumors
- Swedish Cancer Institute, Edmonds
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 lug 2026 · NCT05719558Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 lug 2026 · NCT05098210Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
- Fred Hutch/University of Washington Cancer Consortium, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 6 lug 2026 · NCT06043713LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
- MultiCare Regional Cancer Center, Auburn
- MultiCare Regional Cancer Center, Gig Harbor
- MultiCare Regional Cancer Center, Puyallup
- e altri 2
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 giu 2026 · NCT06216301Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
- VA Puget Sound Health Care System, Seattle
In reclutamentoFase 2
Età 18 e oltre · Uomini · Aggiornato il 15 giu 2026 · NCT05422911BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 2 giu 2026 · NCT06917079A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 1/2
Età 12 e oltre · Tutti i sessi · Aggiornato il 27 mag 2026 · NCT05384626Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 mag 2026 · NCT06757634Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Virginia Mason Medical Center, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 15 mag 2026 · NCT05379985A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
- Virginia Mason Medical Center, Seattle
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 apr 2026 · NCT07020221Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
- Fred Hutchinson Cancer Research Center, Seattle
In reclutamentoFase 2/3
Età 18 e oltre · Tutti i sessi · Aggiornato il 17 apr 2026 · NCT06947928A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Fred Hutchinson Cancer Center, Seattle
In reclutamentoFase 2/3
Tutte le età · Tutti i sessi · Aggiornato il 2 apr 2026 · NCT06581406Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
- Northwest Medical Specialties, PLLC, Tacoma
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 apr 2026 · NCT05735080Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.